Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

FDA authorizes POC antibody test for COVID-19

January 2021—The FDA issued an emergency use authorization for the first serology antibody point-of-care test for COVID-19. The Assure COVID-19 IgG/IgM Rapid Test Device (Azure Biotech) was first authorized in July for emergency use by certain labs to help identify individuals with antibodies to SARS-CoV-2. The EUA has been reissued to authorize the test for POC use using fingerstick blood samples. The lateral flow assay is authorized for use with venous whole blood, serum, plasma, and fingerstick whole blood.

Bio-Rad SARS-CoV-2, flu, RSV run controls

January 2021—Bio-Rad Laboratories launched its SARS-CoV-2, Flu, RSV positive and negative run controls. The products enable laboratories to evaluate day-to-day and lot-to-lot variation of their multiplexed molecular assay and test for operator proficiency.

Roche CE-marked Cobas PIK3CA Mutation Test

January 2021—Roche launched the Cobas PIK3CA Mutation Test CE-IVD for patients with advanced or metastatic breast cancer in countries accepting the CE mark. The test was previously available for research use only.

Saliva-based COVID-19 assay gets EUA

January 2021—Fluidigm received emergency use authorization from the FDA for the Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based test to detect nucleic acid from the SARS‑CoV‑2 virus. The test runs on the Fluidigm Biomark HD microfluidics platform, which can generate as many as 6,000 test results in one day.

Verichem Labs reference materials

December 2020—Protein-based, ready-to-use liquid Matrix Plus Cholesterol Reference kits are available from Verichem Laboratories. The kits are designed to support overall system quality control and CLIA compliance and are for the calibration or calibration verification of cholesterol and uric acid wet assays on clinical testing systems. The materials contain esterified and free cholesterol from bovine serum. The standard kit with the sixth level F covers 12 concentration points; cholesterol concentrations range from 40 to 750 mg/dL and uric acid concentrations from 2 to 30 mg/dL. Active components are verified using standard reference materials from the National Institute of Standards and Technology. Shelf life is 21 months from the date of manufacture. Ready-to-use, liquid Total Protein and Albumin reference materials are also available. The combined Total Protein/Albumin Standard kit, along with the optional standalone Total Protein/Albumin Standard level F, are designed for the calibration and calibration verification of albumin and total protein assays on a wide number of clinical testing systems. The standards are prepared with human serum albumin and gamma-globulin serum proteins in a saline-based solution. Shelf life is 24 months from the manufacturing date.

FDA approves Gavreto for metastatic RET fusion-positive NSCLC

December 2020—Roche announced FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection fusion–positive non-small cell lung cancer as detected by an FDA-approved test. Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.

FDA approves first treatment for COVID-19

December 2020—The FDA approved Gilead Sciences’ antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should be administered only in a hospital or health care setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval.

COVID-19, flu, RSV test available from ARUP

December 2020—ARUP Laboratories announced the availability of a combined test to detect and differentiate COVID-19, influenza, and/or respiratory syncytial virus in individuals with respiratory symptoms consistent with COVID-19. The test can be performed on specimens collected using a deep nasal swab or on specimens collected from the back of the throat and the front of both nostrils.

Siemens, Novartis to develop assays

December 2020—Siemens Healthineers announced a master collaboration agreement with Novartis Pharma to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline. The initial program will focus on developing a serum neurofilament light chain immunoassay for patients with multiple sclerosis and other neurological diseases.

MARKETPLACE

TRENDING